MEREO BIOPHARMA GROUP PLC (MREO) ROE
- 2026-06-30: ROE -98.07%.
- 2026-03-31: ROE -104.86%.
- 2025-12-31: ROE -102.35%.
- 2025-09-30: ROE -89.22%.
Complete source-backed roe history.
- Available history
- 2022-12-31 to 2026-06-30
- Data captured
Historical ROE
| Date | ROE |
|---|---|
| 2026-06-30 | -98.07% |
| 2026-03-31 | -104.86% |
| 2025-12-31 | -102.35% |
| 2025-09-30 | -89.22% |
| 2025-06-30 | -91.46% |
| 2025-03-31 | -78.54% |
| 2024-12-31 | -70.94% |
| 2024-09-30 | 62.47% |
| 2024-06-30 | -46.85% |
| 2024-03-31 | -61.49% |
| 2023-12-31 | -58.31% |
Annual ROE
| Date | ROE |
|---|---|
| 2025-12-31 | -102.35% |
| 2024-12-31 | -70.94% |
| 2023-12-31 | -58.31% |
| 2022-12-31 | -82.14% |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |